Group 1 - The National Health Commission of China has proposed to extend the age limit for blood donors from 55 to 65 years, allowing citizens aged 18 to 65 to donate blood voluntarily if they meet health requirements [1] - The new draft also reduces the interval between blood donations from at least 6 months to at least 90 days, which is expected to improve the stability of blood supply in China [1] Group 2 - Tong Ren Tang announced that it does not hold any equity or investment rights in Sichuan Health Pharmaceutical Co., Ltd., which is involved in the controversy surrounding Antarctic krill oil products [2] - The company emphasized that all its medicines are self-produced and that it will take measures to protect its brand rights amid the ongoing disputes related to the "old brand" [2] Group 3 - Yahui Pharmaceutical received approval from the National Medical Products Administration for the clinical trial application of APL-2401, a first-class innovative drug for advanced solid tumors driven by FGFR2/3 [3] - The approval was granted in just 22 working days, highlighting the support for innovative drugs under the new policy [3] Group 4 - Yuanda Pharmaceutical announced that its self-developed innovative FAP-targeted radiopharmaceutical GPN01530 has received approval from the FDA to conduct I/II phase clinical studies for diagnosing solid tumors [4] - This marks the first FDA approval for a self-developed radiopharmaceutical product from Yuanda, indicating a significant step towards internationalization [4]